Background
Phase 3 double-blind, non-inferiority RCT (Hokusai-VTE). 8,292 patients with acute symptomatic DVT or PE. Compared edoxaban (after initial enoxaparin) to warfarin (after initial enoxaparin). Unlike rivaroxaban/apixaban DOAC-only approaches, Hokusai-VTE used a lead-in period of 5–10 days of parenteral heparin/LMWH before randomization to oral edoxaban or warfarin. Edoxaban is an oral direct factor Xa inhibitor dosed once daily. Dose-reduction criteria: CrCl 30–50 mL/min, weight ≤60 kg, or P-gp inhibitor use → edoxaban 30 mg (vs standard 60 mg).
Interventions and follow up
Arm A: Edoxaban 60 mg once daily (or 30 mg once daily per dose-reduction criteria) for 3–12 months following 5–10 days of initial heparin therapy
Arm B: Warfarin (INR 2.0–3.0) for 3–12 months following 5–10 days of initial heparin therapy
Primary endpoint: Recurrent symptomatic VTE or VTE-related death — non-inferiority margin 1.5 for HR upper CI
mFollow up: Median 12 month
Arm B: Warfarin (INR 2.0–3.0) for 3–12 months following 5–10 days of initial heparin therapy
Primary endpoint: Recurrent symptomatic VTE or VTE-related death — non-inferiority margin 1.5 for HR upper CI
mFollow up: Median 12 month
Results
Recurrent VTE or VTE-related death: 3.2% (edoxaban) vs 3.5% (warfarin); HR 0.89, 95% CI 0.70–1.13 — non-inferior (P<.001 for non-inferiority)
Major or clinically relevant non-major bleeding: 8.5% vs 10.3%; HR 0.81, 95% CI 0.71–0.94 — P=.004 (superiority)
Major bleeding alone: 1.4% vs 1.6%; HR 0.84 (not significant separately)
Major or clinically relevant non-major bleeding: 8.5% vs 10.3%; HR 0.81, 95% CI 0.71–0.94 — P=.004 (superiority)
Major bleeding alone: 1.4% vs 1.6%; HR 0.84 (not significant separately)
Adverse events
Main adverse events: Combined major or CRNMB significantly lower with edoxaban (8.5% vs 10.3%; P=.004). Major bleeding alone not significantly different. Fatal bleeding: 0.1% each arm. Net clinical benefit (recurrent VTE + major bleeding) favored edoxaban. No hepatotoxicity signal. Treatment duration was variable (3–12 months, physician choice).
Conclusions
Edoxaban following initial parenteral anticoagulation was non-inferior to warfarin for acute VTE treatment with significant reduction in combined major/CRNMB bleeding, establishing it as a DOAC option for VTE treatment.
Key Limitations
Key Limitations: Requires initial parenteral anticoagulation (unlike rivaroxaban/apixaban which use an oral lead-in), reducing the single-drug simplicity advantage. Variable treatment duration (3–12 months) was not randomized. Warfarin TTR was 63.5%. The PE subgroup (n=3,319) showed unexpectedly higher recurrence trend in edoxaban (3.9% vs 3.3%), although not statistically significant. Dose-reduction rules for 30 mg are complex and may reduce efficacy in borderline patients.
Clinical Context
FDA approved edoxaban for VTE treatment in January 2015. Edoxaban is the least commonly prescribed DOAC for VTE in the US, partly due to the required parenteral lead-in. However, it is preferred in some patients already on parenteral anticoagulation (e.g., hospitalized for PE) transitioning to oral therapy. The once-daily dosing (vs twice-daily apixaban initial phase) is an advantage for some.
References